Having been the leader for years in the hidradenitis suppurativa (HS) space thanks to Humira, AbbVie Inc. is doubling down on its efforts to advance next-generation treatments for the chronic inflammatory skin condition and moving lutikizumab into Phase III trials.
The US major has announced Phase II results which show that adults with moderate to severe HS who had previously failed anti-TNF therapy and received lutikizumab 300mg every other week or 300mg weekly achieved higher response rates (59.5% and 48.7% respectively) than placebo (35.0%), hitting the primary endpoint of HS clinical response (HiSCR 50), ie, at least a 50% reduction in the total abscess and inflammatory nodule count at week 16. In the 153-adult study, where most (70
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?